The National Institute for Health and Clinical Excellence recommends Baiyueze? (Zebutinib) is used to treat patients with Fahrenheit macroglobulinemia who have previously received at least one treatment

BeiGene has announced that the UK's National Institute for Health and Clinical Excellence (NICE), the UK's health technology assessment body, has published a final assessment document recommending Beyote ® Zebutinib for the treatment of adult patients with

NICE's decision marks the ® first and only conventional drug

WM is a rare B-cell lymphoma that makes up only 2%

Dr Shirley DSa, Consultant and Clinical Leader of the Centre for Hematology at the WM and Related Diseases Centre at University College London, said: "Beaux-Joy ® is a highly selective BTK inhibitor

In this evaluation, NICE believes that Baiyueze ® can be regarded as a "significant advance"

Dr Robert Mulrooney, General Manager of BeiGene, UK and Ireland, said: "I am delighted that NICE has listed NICE ® as an important treatment option for WM patients in England and Wales who meet the treatment standards, which will make WM patients in these areas the first people